Experiences with high dose radiopeptide therapy: The health physics perspective

Gregory D. Espenan, Joseph A. Nelson, Darrell R. Fisher, Daniel S. Diaco, Kevin E. McCarthy, Lowell B. Anthony, Thomas J. Maloney, Eugene A. Woltering

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


One of the new, promising areas of nuclear medicine involves radiolabeled low-molecular-weight peptides for the diagnosis and management of cancer. Somatostatin analogous peptides bind to membrane receptors on tumors with high specificity. These analogues, when radiolabeled with 123I, 131I, 99mTc, or 111In, allow for external scintigraphic imaging or radioguided surgical resection of tumors. Somatostatin analogues with high tumor binding affinity have also been used for high-dose radiotherapy at the Medical Center of Louisiana since 1994. Although we had extensive prior experience with relatively high-dose 131I administration for thyroid ablation, our personnel protection, contamination control, and other safety techniques required significant modification to ensure effective contamination and radiation exposure control. As therapy with radiolabeled peptides becomes more widely utilized, the controls developed at our institution may be implemented by others to maintain exposures ALARA.

Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalHealth Physics
Issue number3
StatePublished - 1999


  • Cancer
  • Medical radiation
  • Nuclear medicine
  • Radiation therapy

ASJC Scopus subject areas

  • Epidemiology
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'Experiences with high dose radiopeptide therapy: The health physics perspective'. Together they form a unique fingerprint.

Cite this